Bennett, D.C., Charest, J., Sebolt, K., Lehrman, M., Rehemtulla, A. and Contessa, J.N. (2013) High-Throughput Screening Identifies Aclacinomycin as a Radiosensitizer of EGFR-Mutant Non-Small Cell Lung Cancer. Translational Oncology, 6, 382-391.
https://doi.org/10.1593/tlo.13232

has been cited by the following article:

• TITLE: New Insights into the Discovery of Novel Drugs to Treat Human Pulmonary Adenocarcinoma

  AUTHORS: Yu Wang, Haishan Zhang, Yingxin Chen, Lining Wang

  KEYWORDS: Cisplatin, Docetaxel, Pemetrexed, Adenocarcinoma, In Vitro, In Vivo, Clinical Trial

  JOURNAL NAME: Journal of Cancer Therapy, Vol.10 No.2, February 21, 2019

  ABSTRACT: Lung cancer is one of the most prevalent cancers in the world. A cisplatin-based chemotherapy regimen is commonly used to major patients who have adenocarcinoma. Because of the limited remission rate, many patients need receive second-line treatment after receiving first-line chemotherapy. Drug screenings carried out currently are mainly from single phase. In consideration of systemic treatment, evaluation of a novel drug candidate from the point of view of first-line and second-line treatment is supposed to be important in the process of drug screening. In this review, we propose a flow of searching for new drugs, which is tailored to accommodate to first-line and second-line treatment in clinic.